Product Details
| Alternative Name: | Interleukin-13, NC30 |
| |
| MW: | ~12.6 kDa |
| |
| Source: | Produced in E. coli. |
| |
| UniProt ID: | P35225 |
| |
| Formulation: | Lyophilized from 20mM sodium phosphate, pH 7.0. |
| |
| Purity: | ≥98% (SDS & HPLC) |
| |
| Purity Detail: | Sterile filtered through a 0.2 micron filter. |
| |
| Endotoxin Content: | Endotoxin level is < 0.1 ng/µg of protein (< 1 EU/µg) |
| |
| Biological Activity: | Determined by its ability to stimulate the proliferation of human TF-1 cells. The expected ED50 is ≤ 1.0 ng/ml, corresponding to a specific activity of ≥ 1 x 106 units/mg. |
| |
| Shipping: | Ambient Temperature |
| |
| Short Term Storage: | -20°C |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | IL-13 (interleukin-13) is primarily produced by activated T cells and has many of the same biological properties as IL-4. IL-13 suppresses the expression of pro-inflammatory cytokines such as IL-1, IL-6, TNF-α and IL-8 by monocytes/macrophages, induces CD23 expression on B cells, promotes B cell proliferation, stimulates secretion of IgE and IgG4, and induces IFN-γ production by NK cells. IL-13 has been shown to inhibit the replication of HIV both in vitro and in vivo. IL-13 induces many phenotypes of allergic lung diseases, including airway hyper responsiveness, goblet cell metaplasia and mucus hypersecretion that contribute to airway obstruction. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Airway Delivery of Hydrogel-Encapsulated Niclosamide for the Treatment of Inflammatory Airway Disease: J. Ousingsawat, et al.; Int. J. Mol. Sci.
23, 1085 (2022),
Abstract;
Expression of SLC26A9 in Airways and Its Potential Role in Asthma: J. Ousingsawat, et al.; Int. J. Mol. Sci.
23, 2998 (2022),
Abstract;
Pro-Inflammatory Activation of A New Immortalized Human Microglia Cell Line: M. Chiavari, et al.; Brain Sci.
9, 111 (2019),
Abstract;
